RT Journal Article SR Electronic T1 Proliferating cell nuclear antigen (PCNA) immunoreactivity in ovarian serous and mucinous neoplasms: diagnostic and prognostic value JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 391 OP 394 DO 10.1046/j.1525-1438.1993.03060391.x VO 3 IS 6 A1 N. Wilkinson A1 C. H. Buckley A1 H. Fox A1 R. J. Hale A1 L. Chawner A1 Li-Na Guo YR 1993 UL http://ijgc.bmj.com/content/3/6/391.abstract AB Sixty-two serous and mucinous ovarian tumors, an admixture of benign, borderline and malignant neoplasms, were immunostained for proliferating cell nuclear antigen (PCNA), with the monoclonal antibody PC10. The PC10 index, the proportion of cells showing nuclear positive staining, was calculated in each case. All the tumors showed positive immunoreactivity for PCNA. There was no overlap of PC10 counts between benign, borderline and malignant serous tumors but within the mucinous group of neoplasms there was considerable overlap between the counts for borderline and malignant tumors. There was no relationship between the PC10 index and the surgical stage of the malignant neoplasms and the index could not be correlated with patient death. Staining for PCNA does not, therefore, appear to be of any prognostic value in ovarian adenocarcinomas.